Intangible Assets

TLSA shows no disclosed brand, patent, or regulatory asset base in the provided metrics, so it lacks evidence of durable pricing power versus peers.

Negative ROIC and ROCE indicate any intangible advantage is not translating into economic returns, which is weaker than peers with proven monetization of IP or brand.

With no visible proprietary content, clinical exclusivity, or licensing leverage in the supplied data, customers and partners appear able to substitute alternatives with limited friction.

Compared with peers that can defend margins through patents, trademarks, or regulated exclusivity, TLSA’s intangible moat appears materially underdeveloped.

Switching Costs

The provided data do not show recurring contracts, embedded workflows, or compliance lock-in, so customer retention is unlikely to be structurally protected versus peers.

A cash conversion cycle of 0 and asset turnover of 0 do not evidence installed-base dependence or renewal stickiness, which are typical sources of switching costs.

Negative invested-capital returns suggest customers are not locked in by a value-creating system that would make replacement costly or risky.

Relative to peers with validated platform integration or long-duration service relationships, TLSA appears to have minimal switching-cost protection.

Network Effects

No evidence in the supplied metrics indicates a user, data, or ecosystem flywheel, so TLSA does not show self-reinforcing demand versus peers.

Negative profitability metrics imply any scale in usage is not yet producing compounding benefits that would strengthen retention or pricing power.

The absence of observable platform dependence means additional customers do not appear to materially increase value for existing customers.

Compared with peers that benefit from two-sided marketplaces, data networks, or developer ecosystems, TLSA shows no discernible network-effect moat.

Cost Advantage

Negative ROIC and ROCE indicate TLSA is not converting capital into returns efficiently, which argues against a structural cost advantage versus peers.

The provided metrics do not show superior asset productivity, scale purchasing, or process efficiency that would support lower unit costs.

With no evidence of operating leverage or persistent margin outperformance, TLSA does not appear able to underprice peers while preserving returns.

Relative to peers with manufacturing scale, proprietary sourcing, or process leadership, TLSA’s cost position looks uncompetitive.

Efficient Scale

The data do not indicate a protected niche, regulated capacity constraint, or local monopoly structure that would support efficient scale versus peers.

Negative returns on capital suggest any scale achieved so far has not created a defensible cost or capacity barrier to entry.

No evidence of market share concentration or industry capacity discipline is present in the supplied metrics, limiting the case for scale-based moat durability.

Compared with peers operating in naturally concentrated markets, TLSA does not show signs of efficient-scale protection.

Overall Score

TLSA shows no clear evidence of a durable economic moat in the supplied data, and its negative ROIC/ROCE reinforce that any competitive advantages are not yet translating into peer-leading economics.